147 related articles for article (PubMed ID: 10562769)
1. New fluoroquinolone antibiotics.
Drug Ther Bull; 1999 Jan; 37(1):6-8. PubMed ID: 10562769
[TBL] [Abstract][Full Text] [Related]
2. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
Goldstein EJ
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S25-30. PubMed ID: 8953103
[TBL] [Abstract][Full Text] [Related]
3. The fluoroquinolones after ciprofloxacin and ofloxacin.
Hooper DC
Curr Clin Top Infect Dis; 2000; 20():63-91. PubMed ID: 10943519
[No Abstract] [Full Text] [Related]
4. A critical review of the fluoroquinolones: focus on respiratory infections.
Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
[TBL] [Abstract][Full Text] [Related]
5. [Pharma-clinics. The drug of the month. Levofloxacin (Tavanic)].
Scheen AJ
Rev Med Liege; 2000 Nov; 55(11):1015-7. PubMed ID: 11195704
[TBL] [Abstract][Full Text] [Related]
6. Levofloxacin.
Norrby SR
Expert Opin Pharmacother; 1999 Nov; 1(1):109-19. PubMed ID: 11249554
[TBL] [Abstract][Full Text] [Related]
7. Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?
Ernst ME; Ernst EJ; Klepser ME
Am J Health Syst Pharm; 1997 Nov; 54(22):2569-84. PubMed ID: 9397218
[TBL] [Abstract][Full Text] [Related]
8. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
Martin SJ; Jung R; Garvin CG
Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
[TBL] [Abstract][Full Text] [Related]
9. Levofloxacin and sparfloxacin: new quinolone antibiotics.
Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
[TBL] [Abstract][Full Text] [Related]
10. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
Langtry HD; Lamb HM
Drugs; 1998 Sep; 56(3):487-515. PubMed ID: 9777318
[TBL] [Abstract][Full Text] [Related]
11. [The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].
Budanov SV; Vasil'ev AN; Smirnova LB
Antibiot Khimioter; 2001; 46(7):38-46. PubMed ID: 11697244
[No Abstract] [Full Text] [Related]
12. Activity of levofloxacin, ofloxacin, D-ofloxacin and ciprofloxacin against systemic and respiratory tract infections in laboratory animals.
Klesel N; Geweniger KH; Koletzki P; Isert D; Limbert M; Markus A; Riess G; Schramm H; Seibert G; Iyer P
Drugs; 1995; 49 Suppl 2():211-4. PubMed ID: 8549307
[No Abstract] [Full Text] [Related]
13. The activity of grepafloxacin against respiratory pathogens in the UK.
Wise R; Andrews JM
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():27-30. PubMed ID: 9484870
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
Wise R; Andrews JM
J Chemother; 1998 Aug; 10(4):276-9. PubMed ID: 9720464
[TBL] [Abstract][Full Text] [Related]
15. Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.
Evans ME
Eur J Clin Microbiol Infect Dis; 2001 Dec; 20(12):883-5. PubMed ID: 11837640
[TBL] [Abstract][Full Text] [Related]
16. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial activity of grepafloxacin.
Wiedemann B; Heisig P
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():19-25. PubMed ID: 9484869
[TBL] [Abstract][Full Text] [Related]
18. Levofloxacin, a second-generation fluoroquinolone.
North DS; Fish DN; Redington JJ
Pharmacotherapy; 1998; 18(5):915-35. PubMed ID: 9758306
[TBL] [Abstract][Full Text] [Related]
19. Grepafloxacin.
Wagstaff AJ; Balfour JA
Drugs; 1997 May; 53(5):817-24; discussion 825-7. PubMed ID: 9129868
[TBL] [Abstract][Full Text] [Related]
20. Safety of the new fluoroquinolones compared with ciprofloxacin.
Ball P
J Chemother; 2000 Jan; 12 Suppl 1():8-11. PubMed ID: 11414383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
